Melissa Pongratz, OD
Optometrist · Goodyear, AZNPI 1508486762
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,708 of the $9,705 with a category attached, or 89.7%. It is spread thinly across 25 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $50.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Biotissue Holdings Inc.$1K
- Bausch & Lomb Americas Inc.$1K
- AbbVie$652
- Tarsus Pharmaceuticals, Inc.$545
- Sun Pharmaceutical Industries Inc.$460
- plus $3K from 19 others
What the payments were for
- Travel & lodging$99710%
- Food & beverage$8,70890%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 19 | $2,005 |
| Biotissue Holdings Inc. | 21 | $1,315 |
| Bausch & Lomb Americas Inc. | 23 | $1,283 |
| AbbVie(2 entities) | 15 | $652 |
| Tarsus Pharmaceuticals, Inc. | 14 | $545 |
| Sun Pharmaceutical Industries Inc. | 9 | $460 |
| Amgen(2 entities) | 38 | $460 |
| Glaukos Corporation | 3 | $402 |
| Oyster Point Pharma, Inc. | 15 | $376 |
| Dompe US, Inc. | 7 | $333 |
| Lumenis BE Inc | 1 | $271 |
| Apellis Pharmaceuticals, Inc. | 3 | $257 |
| Rxsight Inc | 3 | $249 |
| Nova Eye, Inc. | 1 | $232 |
| LKC Technologies, Inc. | 3 | $182 |
| Eyevance Pharmaceuticals LLC | 1 | $172 |
| Sight Sciences, Inc. | 3 | $120 |
| Genmab U.S., Inc. | 1 | $105 |
| Harrow Eye, LLC | 3 | $105 |
| Novartis | 2 | $44 |
| Thea Pharma Inc. | 2 | $44 |
| Kala Pharmaceuticals, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
| Alimera Sciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES TOTAL1 Multifocal$1,297
- AIR OPTIX$1,297
- Dailies Aqua Comfort Plus$1,297
- MIEBO$554
- CEQUA$356
- optilight$271
- VYZULTA$242
- Oxervate$241
- RXSIGHT CONTACT LENS$238
- RXSIGHT INJECTOR CARTRIDGE$238
- RXSIGHT INJECTOR HANDPIECE$238
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$238
- XIIDRA$229
- Tobradex ST$172
- iDoseTR$135
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$129
- VUITY$125
- XDEMVY$125
- RESTASIS MULTIDOSE$125
- Hydrus Microstent$122
How this compares
$9,705 in reported general payments places this provider in the 95th percentile of 1,134 optometrist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 89 | $168,106 |
| RestasisCyclosporine | 100 | $122,612 |
| LumiganBimatoprost | 136 | $78,592 |
| TyrvayaVarenicline Tartrate | 34 | $49,418 |
| XiidraLifitegrast | 22 | $37,295 |
| RocklatanNetarsudil Mesylat/Latanoprost | 51 | $30,803 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,585 |
| VyzultaLatanoprostene Bunod | 31 | $12,204 |
| Prednisolone Acetate | 341 | $11,874 |
| Cyclosporine | 18 | $10,021 |
| Latanoprost | 581 | $7,084 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $7,077 |
| Brimonidine Tartrate | 139 | $5,748 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 275 | $4,908 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $4,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $652 | $208,282261 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $545 | $168,10689 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,283 | $62,08470 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $376 | $49,41834 claims |
| AlconSimbrinza | $2,005 | $4,72121 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $17 | $3,27112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,134 optometrist providers in Arizona.
Other optometrist in Goodyear
- Marc BloomensteinScottsdale$1.4M
- Stephanie WooLake Havasu City$538K
- Jashpal RajasansiGilbert$104K
- Jamie KuhnGlendale$37K
- Tania SobchukLake Havasu City$32K
- Stephen CohenScottsdale$32K
- Andrew ZagelbaumScottsdale$25K
- Linda TrinhPeoria$22K
- Jason BaileyGilbert$17K
- Mike WuTucson$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.